Disposition of 220230 shares by Oliviero James F Iii of Checkpoint Therapeutics at 3.38 subject to Rule 16b-3

CKPT Stock  USD 3.66  0.01  0.27%   
Slightly above 52% of Checkpoint Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Checkpoint Therapeutics suggests that many traders are impartial. Checkpoint Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Checkpoint Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Checkpoint Therapeutics Director, Officer: Ceo, President And Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at macroaxis.com
Disposition of 220230 common stock at 3.38 of Checkpoint Therapeutics by Oliviero James F Iii on 19th of December 2024. This event was filed by Checkpoint Therapeutics with SEC on 2024-12-19. Statement of changes in beneficial ownership - SEC Form 4

Checkpoint Therapeutics Fundamental Analysis

We analyze Checkpoint Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Checkpoint Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Checkpoint Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Price To Earning

Price To Earning Comparative Analysis

Checkpoint Therapeutics is currently under evaluation in price to earning category among its peers. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

Checkpoint Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Checkpoint Therapeutics stock to make a market-neutral strategy. Peer analysis of Checkpoint Therapeutics could also be used in its relative valuation, which is a method of valuing Checkpoint Therapeutics by comparing valuation metrics with similar companies.

Peers

Checkpoint Therapeutics Related Equities

CUECue Biopharma   25.90   
0%
100.0%
RVPHReviva Pharmaceuticals   3.68   
0%
14.0%
FBIOPFortress Biotech   2.80   
0%
10.0%
KODKodiak Sciences   2.19   
0%
8.0%
ACHLAchilles Therapeutics   1.75   
0%
6.0%
FBIOFortress Biotech   1.35   
0%
5.0%
CTMXCytomX Therapeutics   0.88   
0%
3.0%
XOMAOXOMA   0.16   
0%
1.0%
ASMBAssembly Biosciences   0.80   
3.0%
0%
TILInstil Bio   1.26   
4.0%
0%
SPROSpero Therapeutics   1.82   
7.0%
0%
ATXIAvenue Therapeutics   3.40   
13.0%
0%
MBIOMustang Bio   4.55   
17.0%
0%
ALRNAileron Therapeutics   8.33   
32.0%
0%

Additional Tools for Checkpoint Stock Analysis

When running Checkpoint Therapeutics' price analysis, check to measure Checkpoint Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Checkpoint Therapeutics is operating at the current time. Most of Checkpoint Therapeutics' value examination focuses on studying past and present price action to predict the probability of Checkpoint Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Checkpoint Therapeutics' price. Additionally, you may evaluate how the addition of Checkpoint Therapeutics to your portfolios can decrease your overall portfolio volatility.